The comparison of paroxetine and gabapentin in the management of postmenopausal symptoms

Firoozeh  Veisi; Tabassom  Azadian; Maryam  Zangeneh

doi:10.30574/gscbps.2021.15.2.0122

Authors

Firoozeh Veisi Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical sciences, Kermanshah, Iran.
Tabassom Azadian Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical sciences, Kermanshah, Iran.
Maryam Zangeneh Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical sciences, Kermanshah, Iran.

DOI:

https://doi.org/10.30574/gscbps.2021.15.2.0122

Keywords:

Gabapentin, Paroxetine, Menopause, Hot flashes

Abstract

Objective: To compare the clinical efficacy of gabapentin, an anticonvulsant agent, and paroxetine, a selective serotonin reuptake inhibitor in the management of post-menopausal symptoms.

Methods: In this clinical trial, two groups of patients with menopause who had hot flashes were included. One group received gabapentin (600 mg daily, 23 cases) for 8 weeks. The other group received paroxetine (one capsule daily at the morning or at bedtime, 23 cases) for 8 weeks. The MRS (Menopause Rating Scale) as well as the Beck’s Depression Inventory were used to assess the efficacy of the studied medications.

Results: In paroxetine and gabapentin groups, hot flashes, sleep problems, muscle/joint pains, depression, irritability, anxiety, memory problems, and lack of concentration severity significantly decreased after 8 weeks of treatment. Only urinary problems in two treatment groups did not show any significant difference. There was no significant difference in dryness and burning sensation before and after gabapentin (P> 0.05). However, these changes were significant in paroxetine group (P <0.05).

Conclusion: Both paroxetine and gabapentin were effective options in decreasing the severity of menopausal symptoms namely hot flashes, heart discomfort, sleep problems, and muscle/joint pains. In addition, the two medications had favorable results regarding psychological aspects of menopause.

Metrics

Metrics Loading ...

References

Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015; 44(3): 497-515.

Reed SD, Lampe JW, Qu C, Copeland WK, Gundersen G, Fuller S, et al. Premenopausal vasomotor symptoms in an ethnically diverse population. Menopause. 2014; 21(2): 153-8.

Whiteley J, DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health (Larchmt). 2013; 22(11): 983-90.

Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health. 2015; 7: 615-24.

Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. Jama. 2003; 290(13): 1739-48.

de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316-37.

Handley AP, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract. 2015; 27(1): 54-61.

Simon JA, Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K, Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013; 20(10): 1027-35.

Slaton RM, Champion MN, Palmore KB. A review of paroxetine for the treatment of vasomotor symptoms. J Pharm Pract. 2015; 28(3): 266-74.

Hall E, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs. 2011; 71(3): 287-304.

Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005; 366(9488): 818-24.

Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther. 2009; 31(2): 221-35.

Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008; 15(2): 310-8.

Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol. 1995; 5(1): 5-13.

Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004; 2: 45.

Blumel JE, Arteaga E, Parra J, Monsalve C, Reyes V, Vallejo MS, et al. Decision-making for the treatment of climacteric symptoms using the Menopause Rating Scale. Maturitas. 2018; 111: 15-19.

Dormaenen A, Heimdal MR, Wang CE, Grimsgaard AS. Depression in postmenopause: a study on a subsample of the Acupuncture on Hot Flushes among Menopausal Women (ACUFLASH) study. Menopause. 2011; 18(5): 525-30.

Saadati N, Mohammadjafari R, Natanj S, Abedi P. The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: a randomized controlled trial. Glob J Health Sci. 2013; 5(6): 126-30.

Hayes LP, Carroll DG, Kelley KW. Use of gabapentin for the management of natural or surgical menopausal hot flashes. Ann Pharmacother. 2011; 45(3): 388-94.

Rahmanian M, Mohseni A, Ghorbani R. A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women. Int J Gynaecol Obstet. 2015; 131(1): 87-90.

Rada G, Capurro D, Pantoja T, Corbalan J, Moreno G, Letelier LM, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev. 2010; (9): Cd004923.

Albertazzi P, Bottazzi M, Purdie DW. Gabapentin for the management of hot flushes: a case series. Menopause. 2003; 10(3): 214-7.

Reddy SY, Warner H, Guttuso T, Jr, Messing S, DiGrazio W, Thornburg L, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006; 108(1): 41-8.

Singhal SR, Shullai WK. Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms. J Midlife Health. 2016; 7(3): 132-139.

Agarwal N, Singh S, Kriplani A, Bhatla N, Singh N. Safety and efficacy of gabapentin in management of psychosomatic and sexual symptoms in postmenopausal women: A pilot study. J Midlife Health. 2015; 6(1): 10-5.